Abstract
Background and Aims Digital interventions are effective for reducing alcohol consumption but evidence is limited regarding smartphone apps. Drink Less is a theory- and evidence-informed app to help people reduce their alcohol consumption that has been refined in terms of its content and design for usability across the socio-demographic spectrum. We aim to evaluate the effectiveness and cost-effectiveness of recommending Drink Less at reducing alcohol consumption compared with usual digital care.
Design Two-arm individually randomised controlled trial.
Setting Online trial in the UK.
Participants Hazardous or harmful drinkers (Alcohol Use Disorders Identification Test score >=8) aged 18+, and want to drink less alcohol (n=5,562). Participants will be recruited from July 2020 to May 2022 using multiple strategies with a focus on remote digital methods.
Intervention and comparator Participants will be randomised to receive either an email recommending that they use Drink Less (intervention) or view the NHS webpage on alcohol advice (comparator).
Measurements The primary outcome is change in self-reported weekly alcohol consumption between baseline and 6-month follow-up. Secondary outcomes include the proportion of hazardous drinkers; alcohol-related problems and injury; health-related quality of life, and use of health services assessed at 6-month follow-up. Effectiveness will be examined with one-way ANCOVAs, adjusting for baseline alcohol consumption, and using an intention-to-treat approach. A mixed-methods process evaluation will assess engagement, acceptability and mechanism of action. Economic evaluations will be conducted using both a short- and longer-term time horizon.
Comments This study will establish the effectiveness and cost-effectiveness of the Drink Less app at reducing alcohol consumption among hazardous and harmful adult drinkers and will be the first RCT of an alcohol reduction app for the general population in the UK. This study will inform the decision on whether it is worth investing resources in large-scale implementation.
Competing Interest Statement
CG, EP, MM, MF, MO, GL and SM have no conflicts of interest in undertaking this research. JB and EB have received unrestricted funding related to smoking cessation research. JB sits on the scientific advisory board for the SmokeFree app. MH has received unrestricted speaker fees in the last 5 years from MSD, Gillead, Abbvie unrelated to this project. EK led two Cochrane Collaboration reviews in the field of screening and brief alcohol interventions including digital interventions and is currently leading an NIHR School of Public Health Research project which involves a network meta-analysis bringing together both bodies of evidence. She has no other conflicts of interest to declare. MF received funding from Alcohol Change UK in 2019 to conduct a rapid evidence review of digital interventions for the reduction of alcohol-related harm. FG is employed by both PHE and Imperial; he has no other conflicts of interest. RB is a visiting researcher at Kings College London and the University of Southampton, and has done consultancy for WHO Europe; she has no other conflicts of interest. CA has received funding for commissioned research from Systembolaget, the Swedish government-owned alcohol retail monopoly, and Alko, its Finnish equivalent; he has no other conflicts of interest.
Clinical Trial
ISRCTN64052601
Funding Statement
This project is funded by the National Institute for Health Research (NIHR) [Public Health Research Programme (project reference NIHR127651)]. The views expressed are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care, or Public Health England (PHE).
CG, EB and JB are also funded by Cancer Research UK (CRUK: C1417/A22962). Drink Less was funded by the NIHR School for Public Health Research (SPHR), the UK Centre for Tobacco and Alcohol Studies (UKCTAS), the Society for the Study of Addiction (SSA) and CRUK. EP is supported by the NIHR ARC North Thames. MH acknowledges NIHR Health Protection Research Unit in Evaluation, and MM and MH acknowledge NIHR Biomedical Research Centre at Bristol. JB and MM are part of the SPECTRUM Consortium, UK.
The funders played no role in the design, conduct or analysis of the study, nor in the interpretation or reporting of study findings.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval has been obtained from UCL Research Ethics Committee (16799/001).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Trial registration: ISRCTN64052601.
Ethics committee approval: 16799/001.
Data Availability
Study materials, anonymised data and code will be made available on Open Science Framework (on the project page: osf.io/q8mua).